J. Goldman & Co’s Travere Therapeutics TVTX Stock Holding History

J. Goldman & Co’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-35,000	Closed	-$839K	–	320
2015 Q1	$839K	Buy	+35,000	New	+$534K	0.05%	233

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

J. Goldman & Co's TVTX Position: Q1 2025 in Review

J. Goldman & Co sold out of Travere Therapeutics (TVTX) in Q1 2025, closing a stake of 181,174 shares — an estimated $3.16M sold.

J. Goldman & Co first reported a position in TVTX in Q1 2015 and held it in 9 quarters. The position peaked at $4.55M in Q1 2019. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.

J. Goldman & Co reported no remaining Travere Therapeutics position as of Q1 2025 after selling out during the quarter.
J. Goldman & Co sold 181,174 Travere Therapeutics shares in Q1 2025, an estimated $3.16M.
J. Goldman & Co first reported a position in Travere Therapeutics in Q1 2015 and held it in 9 quarters.
J. Goldman & Co's Travere Therapeutics position peaked at $4.55M in Q1 2019.
218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.

Based on J. Goldman & Co's 13F filing for Q1 2025, filed 15 May 2025.